A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 in Patients With Psychosis Associated With Alzheimer's Disease
Latest Information Update: 22 Feb 2025
At a glance
- Drugs Lumateperone (Primary)
- Indications Alzheimer's disease; Psychiatric disorders
- Focus Therapeutic Use
- Sponsors Intra-Cellular Therapies
- 07 May 2024 According to an Intra-Cellular Therapies Media release, company anticipates commencing patient enrollment in the second quarter of 2024.
- 14 Mar 2023 New trial record
- 01 Mar 2023 According to Intra-cellular media release, company plans to begin phase II study in patients with pyschosis in AD.